GMX Reliance Gen.

RNS Number:9750Q
AIM
08 February 2007


          ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2

ALL APPLICANTS MUST COMPLETE THE FOLLOWING:

COMPANY NAME:

GeneMedix plc ("GeneMedix")


COMPANY ADDRESS:

Rosalind Franklin House
Fordham Road
Newmarket


COMPANY POSTCODE:

CB8 7XN


COUNTRY OF INCORPORATION:

United Kingdom

COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED IN
ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:

GeneMedix is a UK-based biopharmaceutical company specialising in the development and manufacture of biosimilar
pharmaceuticals.

DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which
it seeks admission and the number and type to be held as treasury shares):

157,845,140 ordinary shares of 10p each in GeneMedix.
No shares will be held in treasury on admission.


CAPITAL TO BE RAISED ON ADMISSION:

Approximately #14.6 million before expenses.


FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:
Directors:

Dr Kim Tan (Non-Executive Chairman)
Julian Attfield (Chief Executive Officer)
Steve Harris (Non-Executive Director)
Gordon Mylchreest (Non-Executive Director)
Dr H H Ting (Asia Director)



PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL
BEFORE AND AFTER ADMISSION:

Before Admission:                                     (%)
                                                   
Dr Kim Tan                                          34.66
Dr H H Ting                                          4.66
Institute of Cell Biology in China                   5.71
Raffles Nominees                                     5.54


After Admission: :                                    (%)
Reliance Life Sciences Private Limited              74.01
Dr Kim Tan                                            9.3


NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

N/A


ANTICIPATED ACCOUNTING REFERENCE DATE:

30 November


EXPECTED ADMISSION DATE:

16 February 2007


NAME AND ADDRESS OF NOMINATED ADVISER:

Ernst & Young LLP
1 More London Place
London
SE1 2AF


NAME AND ADDRESS OF BROKER:

The Share Centre
PO Box 2000,
Aylesbury,
Bucks,
HP21 8ZB


DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT
THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

As a quoted applicant, GeneMedix is not required to produce an admission document. However, details about the
applicant and the admission of its securities are available at www.genemedix.com.



DATE OF NOTIFICATION:

8 February 2007


NEW/ UPDATE (see note):


UPDATE


QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:

THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED:


Official List


THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:


30 November 2000


CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY
REQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET:


The Directors of GeneMedix confirm that, following due and careful enquiry, the Company has adhered to the legal
and regulatory requirements involved in having its securities traded on the Official List.


AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE
LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE:


www.genemedix.com


DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS
OF ITS INVESTMENT STRATEGY:


GeneMedix will continue to build on existing development and manufacturing programmes for biosimilar
pharmaceuticals.


A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED
SINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:




Save for significant change arising out of increased losses brought about by normal expenditure; there has been
no significant change in financial or trading position of GeneMedix, which has occurred since 30 November 2005,
being the end of the financial period for which audited statements have been published.


A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILABLE TO
IT OR ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:


The directors of GeneMedix have no reason to believe that the Group has insufficient working capital for its
present requirements, that is, for at least the next 12 months from the date of this announcement.


DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:


Reliance Life Sciences Private Limited, and directors of GeneMedix; Dr Kim Tan, Gordon Mylchreest, and Julian
Attfield; have agreed not to dispose of any interest in GeneMedix's securities for one year from the date of
admission.


A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES:


CREST


A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES:


www.genemedix.com


INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC:


Additional information may be found at www.genemedix.com.


A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A
FINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION AND INTERIM RESULTS WHERE APPLICABLE.  THE
ACCOUNTS MUST BE PREPARED IN ACCPRDANCE WITH ACCOUNTING STANDARDS PERMISSIBLE UNDER AIM RULE 19:


http://www.genemedix.com/fin.asp


THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY:


GeneMedix currently holds no shares in treasury.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AIMTPMFTMMMMBIR

Reliance Genemedix (LSE:GMX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Reliance Genemedix (LSE:GMX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024